Presspart Nemo, the new specialist injection moulding division of Presspart, has begun manufacturing a six-piece nasal drug delivery device for GlaxoSmithKline’s Avamys (fluticasone furoate), an intranasal corticosteroid treatment for allergic rhinitis.
Presspart is the world’s leading provider of specialist metal and plastic components to the pharmaceutical industry, and Nemo develops precision plastic parts according to customer requirements. Bringing together the two companies’ complementary capabilities provides opportunities to offer novel solutions to the pharmaceutical industry.
The Avamys device is produced at the company’s facilities in Spain, where it recently introduced a lean manufacturing approach to reduce waste and energy consumption, while maintaining high standards of quality control.
“The Avamys device is a great example of Presspart Nemo’s injection-moulding know how,” said Ramón Marqués, managing director at Presspart Nemo. “We are planning a range of extensions to our product offerings for the future in continuing to expand Presspart Nemo’s capabilities.”